event recap

Delivering better outcomes for America's seniors

July 12, 2019

A discussion with Welltower CEO Tom DeRosa

The aging U.S. population is growing at its fastest rate in history. This large-scale demographic change brings with it new challenges — challenges that need innovative solutions.

In June, Tom DeRosa, CEO of Welltower and a MATTER board member, joined us at MATTER to share advice on how healthcare companies can deliver better care to the aging popula…

Read more

event recap

How can tech make the end of life more human?

July 10, 2019

A discussion with Dr. Shoshana Ungerleider

Last month, we hosted a screening of End Game, the Netflix documentary The New York Times calls a provocative and intimate look at how doctors, nurses and patients cope with death.

What’s it going to take for us to see talking about care at the end of life as a normal wellness practice? -@ShoshUMD #RoadtoEndWell— MATT…

Read more

stories that matter

#storiesthatmatter: Maneuvering care after trauma

July 2, 2019

For many who have chosen a career in healthcare, their work is more than a job — it’s personal.

Next from Stories That Matter: We’re teaming up with our partners at Horizon Therapeutics to spotlight Horizon employees whose personal experiences within the healthcare system have uniquely equipped them for their careers.

As a patient access manager at Horizon, Dorelia Rivera spends each day help…

Read more

member news

Startup Shoutouts: June 28, 2019

June 28, 2019

Every day, innovators across the MATTER community are building new solutions that accelerate innovation, advance care and improve lives. Here’s a look into the most noteworthy headlines from the past few weeks.

Vynca scores $10.3M to honor end-of-life wishes

Vynca, a leading advance care planning solution, received $10.3 million in Series B funding from strategic investors including First Tru…

Read more


Building a mission-driven company: A fireside chat with Forty Seven, Inc.’s Dr. Mark Chao and Mark McCamish

June 26, 2019

A race is underway to develop the next major checkpoint inhibitor that harnesses the innate immune system.

At the forefront is Forty Seven, Inc., a clinical stage immuno-oncology company founded in 2015 that developed out of a lab at Stanford University. The company focuses on targeting the CD47 pathway as a way to engage macrophages — the body’s first responders — in fighting tumors.

Last mo…

Read more